STATE OF THE ART PAPER
The role of HMGB1 in gastrointestinal cancers
 
More details
Hide details
1
Department of Gastroenterology, Sanko University, Gaziantep, Turkey
 
2
Department of Oncology, School of Medicine, Sanko University, Gaziantep, Turkey
 
3
Department of Medical Biochemistry, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
 
4
Department of Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
 
 
Submission date: 2021-01-26
 
 
Final revision date: 2021-03-02
 
 
Acceptance date: 2021-03-21
 
 
Publication date: 2021-04-16
 
 
Arch Med Sci Civil Dis 2021;6(1):1-7
 
KEYWORDS
TOPICS
ABSTRACT
Despite advances in diagnostic and therapeutic methods, gastrointestinal (GI) cancers have both a high incidence and a high mortality rate. In addition to surgery, chemotherapy and radiotherapy, novel modalities such as immunotherapy are increasingly used in the treatment of these cancers. However, the prognosis in GI cancers remains poor despite the availability of these treatments, which prompted the search for new prognostic and predictive markers. High-mobility group box-1 (HMGB1) is a non-histone DNA protein which is known as a nuclear transcription factor. The search for new therapeutic targets has also gained importance. In this review, the prognostic and predictive role of HMGB1 in gastrointestinal cancers will be discussed in light of current literature.
 
REFERENCES (57)
1.
Güthle M, Ettrich T, Seufferlein T. Immunotherapy in gastrointestinal cancers. Visc Med 2020; 36: 231-37.
 
2.
Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 2009; 37: 1107-14.
 
3.
Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990; 1049: 231-43.
 
4.
Alexandrova EA, Beltchev BG. Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun 1988; 154: 918-27.
 
5.
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
 
6.
Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010; 337: 251-8.
 
7.
Yan HX, Wu HP, Zhang HL, et al. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013; 59: 762-8.
 
8.
Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009; 34: 425-31.
 
9.
Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007; 28: 1957-67.
 
10.
Zhang X, Yu J, Li M, Zhu H, Sun X, Kong L. The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: a meta-analysis and literature review. Onco Targets Ther 2016; 9: 4901-11.
 
11.
Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 2012; 103: 1714-21.
 
12.
Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-70.
 
13.
Thomas JO, Travers AA. HMG1 and 2, and related ‘architectural’ DNA binding proteins. Trends Biochem Sci 2001; 26: 167-74.
 
14.
Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73- dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002; 277: 7157-64.
 
15.
Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203: 1637-42.
 
16.
Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008; 20: 518-23.
 
17.
Gdynia G, Sauer SW, Kopitz J, et al. The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nat Commun 2016; 7: 10764.
 
18.
Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Murata M. Crosstalk between DNA damage and inflammation in the multiple steps of carcinogenesis. Int J Mol Sci 2017; 18: 1808.
 
19.
Pistoia V, Pezzolo A. Involvement of HMGB1 in resistance to tumor vessel-targeted, monoclonal antibody-based immunotherapy. J Immunol Res 2016; 2016: 3142365.
 
20.
Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28:367-88.
 
21.
Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005; 78: 1-8.
 
22.
Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-7.
 
23.
Fearon ER, Vogelstein B. A genetic model for colorectal tumourigenesis. Cell 1990; 61: 759-67.
 
24.
Faham A, Bennett D, Altin JG. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 2009; 27: 5846-54.
 
25.
Livesey KM, Kang R, Zeh HJ 3rd, Lotze MT, Tang D. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 2012; 8: 846-8.
 
26.
He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 2000; 97: 5768-72.
 
27.
Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 2004; 11: 557-64.
 
28.
Zhang Z, Wang M, Zhou L, et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumour cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res 2015; 34: 51.
 
29.
He S, Cheng J, Sun L, et al. HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect. Cell Death Dis 2018; 9: 648.
 
30.
Li Z, Wang H, Song B, Sun Y, Xu Z, Han J. Silencing HMGB1 expression by lentivirus-mediated small interfering RNA (siRNA) inhibits the proliferation and invasion of colorectal cancer LoVo cells in-vitro and in-vivo. Zhonghua Zhong Liu Za Zhi 2015; 37: 664-70.
 
31.
Peng RQ, Wu XJ, Ding Y, et al. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer 2010; 10: 496.
 
32.
Li Z, Wang H, Song B, et al. Expression of high mobility group box-1 in colorectal cancer and its clinical significance. Chin J Gastrointest Surg 2015; 18: 616-9.
 
33.
Wang CQ, Huang BF, Wang Y, et al. Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis. Sci Rep 2020; 10: 18587.
 
34.
Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006; 55: 234-42.
 
35.
Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box-1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010; 136: 677-84.
 
36.
Huang M, Geng Y, Deng Q, et al. Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway. Int J Oncol 2018; 53: 1481-92.
 
37.
Zhu L, Li X, Chen Y, Fang J, Ge Z. High-mobility group box 1: a novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett 2015; 357: 527-34.
 
38.
Sharma S, Evans A, Hemers E. Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group box 1. Cell Tissue Res 2016; 365: 357-66.
 
39.
Xiao B, Chen D, Luo S, et al. Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/MMP9 signaling. Oncotarget 2016; 7: 50057-73.
 
40.
Lee H, Song M, Shin N, et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 2012; 7: 34318.
 
41.
Liu DB. Prognostic research of transgelin, MMP-7 and HMGB1 Protein Expression in Rectal cancer [graduation thesis]. An Hui Medical University 2013.
 
42.
Suren D, Arda Gokay A, Sayiner A. High mobility group box 1 (HMGB1) expression in gastric adenocarcinomas. J BUON 2018; 23: 422-7.
 
43.
Zhang J, Kou YB, Zhu JS, Chen WX, Li S. Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-B pathway in vitro and in vivo. Int J Oncol 2014; 44: 1268-76.
 
44.
Zhan Z, Li Q, Wu P, et al. Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy 2012; 8: 109-21.
 
45.
Li ZJ, Song B, Liu J, et al. Inhibitory effect of silencing of HMGB1 gene expression on the invasive and metastatic abilities of MGC-803 gastric cancer cells. Zhonghua Zhong Liu Za Zhi 2013; 35: 244-8.
 
46.
Song B, Song WG, Li ZJ, et al. Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC-803 gastric cancer cells. Cell Biochem Funct 2012; 30: 11-7.
 
47.
Wang ZQ, Tao H, Ma YF, et al. Aloin induces apoptosis via regulating the activation of MAPKs signaling pathway in human gastric cancer cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2018; 38: 1025-31.
 
48.
Tao H, Tang T, Wang S, et al. The molecular mechanisms of Aloin induce gastric cancer cells apoptosis by targeting high mobility group box 1. Drug Design Develop Ther 2019; 13: 1221-31.
 
49.
Takeda T, Izumi H, Kitada S, et al. The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2014; 35: 10555-69.
 
50.
Kang R, Tang D, Schapiro NE, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 2014; 33: 567-77.
 
51.
Swami P, Thiyagarajan S, Vidger A, et al. RAGE up-regulation differently affects cell proliferation and migration in pancreatic cancer cells. Int J Mol Sci 2020; 21: 7723.
 
52.
Kang R, Xie Y, Zhang Q, et al. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res 2017; 27: 916-32.
 
53.
Kamo N, Ke B, Ghaffari AA, Busuttil RW, Cheng G, Kupiec-Weglinski JW. ASC/caspase-1/IL-1beta signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology 2013; 58: 351-62.
 
54.
Dong YD, Cui L, Peng CH, Cheng DF, Han BS, Huang F. Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumour growth and metastasisin vitro and in vivo. Oncol Rep 2013; 29: 87-94.
 
55.
Yan W, Chang Y, Liang X, et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012; 55: 1863-75.
 
56.
Lu L, Zhang D, Xu Y, Bai G, Lv Y, Liang J. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1. Biomed Pharmacother 2018; 104: 613-21.
 
57.
Xiao J, Ding Y, Huang J, et al. The association of HMGB1 gene with the prognosis of HCC. PLoS One 2014; 9: 89097.
 
ISSN:2451-0637
Journals System - logo
Scroll to top